These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
353 related articles for article (PubMed ID: 19629022)
1. Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities. Oganesian A; Shilling AD; Young-Sciame R; Tran J; Watanyar A; Azam F; Kao J; Leung L Psychopharmacol Bull; 2009; 42(2):47-63. PubMed ID: 19629022 [TBL] [Abstract][Full Text] [Related]
2. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system. Preskorn SH; Nichols AI; Paul J; Patroneva AL; Helzner EC; Guico-Pabia CJ J Psychiatr Pract; 2008 Nov; 14(6):368-78. PubMed ID: 19057238 [TBL] [Abstract][Full Text] [Related]
3. Desvenlafaxine: another "me too" drug? Sopko MA; Ehret MJ; Grgas M Ann Pharmacother; 2008 Oct; 42(10):1439-46. PubMed ID: 18698015 [TBL] [Abstract][Full Text] [Related]
4. In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drug-drug interactions. Wójcikowski J; Danek PJ; Basińska-Ziobroń A; Pukło R; Daniel WA Pharmacol Rep; 2020 Jun; 72(3):612-621. PubMed ID: 32219694 [TBL] [Abstract][Full Text] [Related]
5. Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor. Zhang Y; Guo X; Lin ET; Benet LZ Drug Metab Dispos; 1998 Apr; 26(4):360-6. PubMed ID: 9531525 [TBL] [Abstract][Full Text] [Related]
6. In vitro assessment of cytochrome P450 inhibition and induction potential of felotaxel (SHR110008). Ding Y; Jia Y; Lu C; Liu W; Yang J; Song Y; Zhu Y; Yang L; Ding L; Wen A Biomed Pharmacother; 2012 Jun; 66(4):318-21. PubMed ID: 22397757 [TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of cytochrome P450 2D6 by Sarpogrelate and its active metabolite, M-1, in human liver microsomes. Cho DY; Bae SH; Lee JK; Kim YW; Kim BT; Bae SK Drug Metab Dispos; 2014 Jan; 42(1):33-9. PubMed ID: 24167220 [TBL] [Abstract][Full Text] [Related]
8. An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Etheridge AS; Black SR; Patel PR; So J; Mathews JM Planta Med; 2007 Jul; 73(8):731-41. PubMed ID: 17611934 [TBL] [Abstract][Full Text] [Related]
9. In vitro inhibitory effects of asiaticoside and madecassoside on human cytochrome P450. Winitthana T; Niwattisaiwong N; Patarapanich C; Tantisira MH; Lawanprasert S Toxicol In Vitro; 2011 Jun; 25(4):890-6. PubMed ID: 21349323 [TBL] [Abstract][Full Text] [Related]
10. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Wandel C; Kim RB; Kajiji S; Guengerich P; Wilkinson GR; Wood AJ Cancer Res; 1999 Aug; 59(16):3944-8. PubMed ID: 10463589 [TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of gypenosides on seven human cytochrome P450 enzymes in vitro. He M; Jiang J; Qiu F; Liu S; Peng P; Gao C; Miao P Food Chem Toxicol; 2013 Jul; 57():262-5. PubMed ID: 23583485 [TBL] [Abstract][Full Text] [Related]
12. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine. Owen JR; Nemeroff CB Depress Anxiety; 1998; 7 Suppl 1():24-32. PubMed ID: 9597349 [TBL] [Abstract][Full Text] [Related]
13. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Prueksaritanont T; Gorham LM; Ma B; Liu L; Yu X; Zhao JJ; Slaughter DE; Arison BH; Vyas KP Drug Metab Dispos; 1997 Oct; 25(10):1191-9. PubMed ID: 9321523 [TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect of glyburide on human cytochrome p450 isoforms in human liver microsomes. Kim KA; Park JY Drug Metab Dispos; 2003 Sep; 31(9):1090-2. PubMed ID: 12920163 [TBL] [Abstract][Full Text] [Related]
15. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro. Wandel C; Kim RB; Guengerich FP; Wood AJ Drug Metab Dispos; 2000 Aug; 28(8):895-8. PubMed ID: 10901697 [TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions. Micuda S; Mundlova L; Anzenbacherova E; Anzenbacher P; Chladek J; Fuksa L; Martinkova J Eur J Clin Pharmacol; 2004 Oct; 60(8):583-9. PubMed ID: 15378224 [TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates. Derks M; Fowler S; Kuhlmann O Curr Med Res Opin; 2009 Apr; 25(4):891-902. PubMed ID: 19245299 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106 [TBL] [Abstract][Full Text] [Related]
19. In vitro inhibitory mechanisms and molecular docking of 1'-S-1'-acetoxychavicol acetate on human cytochrome P450 enzymes. Haque AKMM; Leong KH; Lo YL; Awang K; Nagoor NH Phytomedicine; 2017 Jul; 31():1-9. PubMed ID: 28606510 [TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Martínez C; Albet C; Agúndez JA; Herrero E; Carrillo JA; Márquez M; Benítez J; Ortiz JA Clin Pharmacol Ther; 1999 Apr; 65(4):369-76. PubMed ID: 10223772 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]